COVID-19 Vaccine Related Codes

COVID-19 Vaccine Codes

Preview Posting of COVID-19 Vaccine Codes and Crosswalk for Currently Authorized Vaccines and Anticipation of Potential Vaccine Availability under Emergency Use Authorization (EUA)

Note: Codes will become effective only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA)

The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress. Additional vaccines or codes will be added to this list as they enter late-stage clinical trials or prepare applications for FDA authorization.

The following downloadable table provides a summary of the currently authorized vaccine codes and a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines.

To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance.

The codes for these vaccines are also included in the vaccine code set files unless otherwise noted in the table.  Additional code details and fields values are included in the vaccine code sets.

American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA web site.  The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets.  You can access further information regarding the COVID-19 CPT codes, as well as the associated coding guidance, using the following link:

https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codesexternal icon

Download the Preview Table for US vaccine administration only: Excel Versionexcel icon

COVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-EUA) as of 10/29/2021. Codes will become effective for US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 vaccine(s) by the FDA. All CVX codes are associated to the new Vaccine Group “COVID-19.” CPT Codes shown are product codes. CPT administrative codes for doses are available on the AMA website. CPT product codes are added as the AMA approves and makes them available.

COVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-EUA) as of 10/13/2021. Codes will become effective for US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 vaccine(s) by the FDA. All CVX codes are associated to the new Vaccine Group “COVID-19.” CPT Codes shown are product codes. CPT administrative codes for doses are available on the AMA website. CPT product codes are added as the AMA approves and makes them available.
Manufacturer FDA Authorization
(BLA, EUA, Pre-EUA)
Sale Proprietary Name Product Description Unit of Sale NDC10 (UOS) UoS Package Unit of Use NDC10 (UOU) UoU Presentation CVX Code CVX Long Description CVX Short Description MVX Code CPT Product Code CPT Description
Janssen Products, LP EUA-authorized (18+) Janssen COVID-19 Vaccine 5×10^10 viral particles/0.5 mL for adult 18+ 59676-580-15 CARTON, 10 MULTI-DOSE VIALS 59676-580-05 VIAL, MULTI-DOSE 212 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL JSN 91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×1010 viral particles/0.5 mL dosage, for intramuscular use
Moderna US, Inc. EUA-authorized (18+) Moderna COVID-19 Vaccine 100 mcg/0.5 mL for adult 18+ (existing product) 80777-273-99 CARTON, 10 MULTI-DOSE VIAL 5 mL EACH 80777-273-10 VIAL, 5 mL, MULTI-DOSE VIAL 207 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg or 50 mcg dose COVID-19, mRNA, LNP-S, PF, 100 mcg or 50 mcg dose MOD 91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use
80777-273-98 CARTON, 10 MULTI-DOSE VIAL 7 mL EACH 80777-273-15 VIAL, 7 mL, MULTI-DOSE VIAL
Moderna US, Inc. EUA-authorized (18+) Moderna COVID-19 Vaccine 50 mcg/0.25 mL for booster adult 18+ (existing product) 80777-273-99 CARTON, 10 MULTI-DOSE VIAL 5 mL EACH 80777-273-10 VIAL, 5 mL, MULTI-DOSE VIAL 207 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg or 50 mcg dose COVID-19, mRNA, LNP-S, PF, 100 mcg or 50 mcg dose MOD 91306 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use
80777-273-98 CARTON, 10 MULTI-DOSE VIAL 7 mL EACH 80777-273-15 VIAL, 7 mL, MULTI-DOSE VIAL
Pfizer-BioNTech BLA-licensed (16+)

EUA-authorized (12+)

Pfizer-BioNTech COVID-19 Vaccine 30 mcg/0.3 mL ages 12+  (existing product) 59267-1000-2 CARTON, 195 MULTI-DOSE VIALS 59267-1000-1 MULTI-DOSE VIAL 208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose PFR 91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use
59267-1000-3 CARTON, 25 MULTI-DOSE VIALS
Pfizer-BioNTech EUA-authorized (18+) Pfizer-BioNTech COVID-19 Vaccine 30 mcg/0.3 mL for Booster (existing product) 59267-1000-2 CARTON, 195 MULTI-DOSE VIALS 59267-1000-1 MULTI-DOSE VIAL 208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose PFR 91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use
59267-1000-3 CARTON, 25 MULTI-DOSE VIALS
Pfizer-BioNTech EUA-authorized Pfizer-BioNTech COVID-19 Vaccine Tris-sucrose formula, 30 mcg/0.3 mL for ages 12+ 59267-1025-2 CARTON, 195 MULTI-DOSE VIALS 59267-1025-1 VIAL, 2.25 mL, MULTI-DOSE VIAL 217 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose PFR 91305 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
59267-1025-3 CARTON, 25 MULTI-DOSE VIALS
59267-1025-4 CARTON, 10 MULTI-DOSE VIALS
Pfizer-BioNTech EUA-authorized Pfizer-BioNTech COVID-19 Vaccine Tris-sucrose formula, 10 mcg/0.2 mL for ages 5 yrs to < 12 yrs 59267-1055-2 CARTON, 195 MULTI-DOSE VIALS 59267-1055-1 VIAL, 2 mL, MULTI-DOSE VIAL 218 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose PFR 91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
59267-1055-4 CARTON, 10 MULTI-DOSE VIALS
Pfizer-BioNTech Pre-EUA Pfizer-BioNTech COVID-19 Vaccine Tris-sucrose formula, 3 mcg/0.2 mL for ages 2 yrs to < 5 yrs 59267-0078-2 CARTON, 195 MULTI-DOSE VIALS 59267-0078-1 VIAL, 2 mL, MULTI-DOSE VIAL 219 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose PFR TBD TBD
59267-0078-4 CARTON, 10 MULTI-DOSE VIALS
Pfizer-BioNTech BLA-licensed (16+) COMIRNATY 30 mcg/0.3 mL for adult 16+ (existing formula) 00069-1000-02 CARTON, 195 MULTI-DOSE VIALS 00069-1000-01 VIAL, 2 mL, MULTI-DOSE VIAL COMINARTY products are not orderable at this time. NDCs are listed per FDA Structured Product Label (SPL) document for the BLA licensed product.  These codes are not included in CDC Vaccine Code Set files at this time.  Pfizer has provided the following statement regarding the COMINARTY  branded NDCs and labels:

“Pfizer received FDA BLA license on 8/23/2021 for its COVID-19 vaccine for use in individuals 16 and older (COMIRNATY).  At that time, the FDA published a BLA package insert that included the approved new COVID-19 vaccine tradename COMIRNATY and listed 2 new NDCs (0069-1000-03, 0069-1000-02) and images of labels with the new tradename.
At present, Pfizer does not plan to produce any product with these new NDCs and labels over the next few months while EUA authorized product is still available and being made available for U.S. distribution.  As such, the CDC, AMA, and drug compendia may not publish these new codes until Pfizer has determined when the product will be produced with the BLA labels.”

00069-1000-03 CARTON, 25 MULTI-DOSE VIALS
AstraZeneca Pharmaceuticals LP Pre-EUA AstraZeneca COVID-19 Vaccine 5×10^10 viral particles/0.5 mL, adult No active NDC codes for U.S. Market 210 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL ASZ 91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×1010 viral particles/0.5 mL dosage, for intramuscular use
Novavax, Inc. Pre-EUA Novavax COVID-19 Vaccine 5 mcg/0.5 mL, adult No active NDC codes for U.S. Market 211 SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose COVID-19 vaccine, Subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL NVX 91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use

Unspecified US COVID-19 Vaccine CVX Code

Unspecified US COVID-19 Vaccine CVX Code
CVX Short Description CVX Code CVX Long Description Note Vaccine Status
SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED 213 SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED Unspecified code for COVID-19 not to be used to record patient US administration. May be used to record historic US administration if product is not known.  CVX code 500 should be used to record Non-US vaccine where product is not known. Inactive

Download the Preview Table for Non-US vaccine administration only: Excel Versionexcel icon

Preview Posting of COVID-19 Vaccine Codes and Crosswalks to be used for Non-US vaccine administration. All COVID-19 related CVX codes are associated to the Vaccine Group “COVID-19”. Data as of 11/15/2021. CVX and MVX codes are identified for vaccines that have received emergency authorization from the World Health Organization (WHO), US Food and Drug Administration (FDA) or both. CVX codes have also been added without associated MVX for vaccines that are manufactured and administered outside the US but which have not been authorized by the WHO. The list of vaccines not authorized by the WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC monitors WHO published information.

Preview Posting of COVID-19 Vaccine Codes and Crosswalks to be used for Non-US vaccine administration. All COVID-19 related CVX codes are associated to the Vaccine Group “COVID-19”. Data as of 10/13/2021. CVX and MVX codes are identified for vaccines that have received emergency authorization from the World Health Organization (WHO), US Food and Drug Administration (FDA) or both. CVX codes have also been added without associated MVX for vaccines that are manufactured and administered outside the US but which have not been authorized by the WHO. The list of vaccines not authorized by the WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC monitors WHO published information.
CVX Code CVX Long Description CVX Short Description CVX Note CVX Status MVX Code MVX Manufacturer Product Tradename(s)
207 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg or 50 mcg dose COVID-19, mRNA, LNP-S, PF, 100 mcg or 50 mcg dose EUA 12/18/2020, 2-dose vaccine. Used to record Moderna vaccines administered in the US and in non-US locations (includes tradename Spikevax) Active MOD Moderna US, Inc. Moderna COVID-19 Vaccine (non-US Spikevax)
208 SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose EUA 12/11/2020, 2-dose vaccine. Used to record Pfizer vaccines administered in the US and in non-US locations (includes tradename Comirnaty) Active PFR Pfizer, Inc Pfizer-BioNTech COVID-19 Vaccine (US-EUA), COMIRNATY (US-BLA), COMIRNATY (Non-US)
210 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL Potential EUA, 2-dose vaccine. AstraZeneca vaccine is authorized by the WHO and recognized towards immunity in the US. Non-US WHO authorized tradenames/identifiers include VAXZEVRIA, AZD1222, ChAdOx1 nCoV-19, COVISHIELD Non-US ASZ AstraZeneca AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)
212 SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL EUA 02/27/2021, 1-dose vaccine. Used to record Janssen/J&J vaccines administered in the US and in non-US locations Active JSN Janssen Janssen (J&J) COVID-19 Vaccine
510 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm) COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) WHO authorized pandemic vaccine. Recognized towards immunity in US Non-US SPH Sinopharm-Biotech Sinopharm (BIBP) COVID-19 Vaccine
511 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac) COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) WHO authorized pandemic vaccine. Recognized towards immunity in US Non-US SNV Sinovac Coronavac (Sinovac) COVID-19 Vaccine
500 SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown COVID-19 Non-US Vaccine, Product Unknown Pandemic Non-US Covid Administration – specific CVX or product unknown Non-US
501 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN) COVID-19 IV Non-US Vaccine (QAZCOVID-IN) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
502 SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN) COVID-19 IV Non-US Vaccine (COVAXIN) Pandemic Non-US Vaccine Authorized by WHO 11-3-2021, recognized toward immunity in US, https://extranet.who.int/pqweb/vaccines/who-recommendation-bharat-biotech-international-ltd-covid-19-vaccine-whole-virion Non-US BBI Bharat Biotech International Limited COVAXIN (Bharat) COVID-19 Vaccine
503 SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC) COVID-19 LAV Non-US Vaccine (COVIVAC) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
504 SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light) COVID-19 VVnr Non-US Vaccine (Sputnik Light) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
505 SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V) COVID-19 VVnr Non-US Vaccine (Sputnik V) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
506 SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CanSino Biological Inc./Beijing Institute of Biotechnology) COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
507 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences) COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
508 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention) COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US
509 SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona) COVID-19 PS Non-US Vaccine (EpiVacCorona) Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US Non-US

COVID-19 Emergency Use Authorization Recipient and Caregiver Fact Sheets

Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers

Vaccine information statements (VISs), used only for licensed vaccines, will not be available for COVID-19 vaccines while they are under Emergency Use Authorization (EUA). For vaccines under an EUA, the FDA requires a vaccine-specific Fact Sheet for Recipients and Caregivers be provided to vaccine recipients or their caregivers.

The COVID-19 vaccine-related codes are provided in anticipation of potential vaccine availability under an EUA. If a vaccine is not authorized, the code will be retired.

The FDA issued Emergency Use Authorization for the Moderna COVID-19 vaccine on Friday December 18, 2020.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccineexternal icon

The FDA issued Emergency Use Authorization for the Pfizer BioNTech COVID-19 vaccine on Friday December 11, 2020.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccineexternal icon

The FDA issued Emergency Use Authorization for the Janssen (Johnson & Johnson) COVID-19 vaccine on Saturday February 27, 2021.  Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccineexternal icon

The following downloadable VIS code files will include the new EUA Fact Sheet for Recipients records:

Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers”
CVX Code EUA Recipient/Caregiver Fact Sheet Description Document Barcode String Edition Date Edition Status HTML URL PDF URL VIS GDTI document code
207 COVID-19 Moderna Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300034911210601 11/19/2021 Current https://www.cdc.gov/vaccines/covid-19/eua/modernatx.html https://www.cdc.gov/vaccines/covid-19/eua/modernatx.pdfpdf icon 0886983000349
208, 217 COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet 253088698300033211210501 11/19/2021 Current https://www.cdc.gov/vaccines/covid-19/eua/pfizer.html https://www.cdc.gov/vaccines/covid-19/eua/pfizer.pdfpdf icon 0886983000332
218 COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet-Pediatric 253088698300042411211001 10/29/2021 Current https://www.cdc.gov/vaccines/covid-19/eua/pfizer-children.html https://www.cdc.gov/vaccines/covid-19/eua/pfizer-children.pdfpdf icon 0886983000424
212 COVID-19 Janssen Vaccine EUA Recipient-Caregiver Fact Sheet 253088698300036311210201 10/20/2021 Current https://www.cdc.gov/vaccines/covid-19/eua/janssen.html https://www.cdc.gov/vaccines/covid-19/eua/janssen.pdfpdf icon 0886983000363

*Edition Date represents the date of update printed on the actual fact sheet document published by the FDA.  It may not be the same as the EUA authorization date or the date embedded in the Document Barcode String.

Page last reviewed: November 19, 2021